Cerebrein, a brain dysfunction improvement drug, exceeds original drug imports
Oct 24, 2025
|
According to the latest data from the Ministry of Food and Drug Safety, Cerebrain's production performance reached 6.1 billion won, exceeding Cerebrain's original drug imports of 5.6 billion won.
Cerebrain's sales are also growing fast. Since its official launch in 2021, it has continued to grow rapidly, with an average annual growth rate of about 78.8% until last year. Even considering that sales in the first year are small and growth rates can be high, the pace of growth is very unusual.
Daewoong Bio aims to achieve 8 billion won in sales this year and 10 billion won next year. In addition, prescription institutions are steadily expanding as they are introduced to major general hospitals such as Seoul National University Hospital, Seoul Asan Hospital, and Seoul St. Mary's Hospital.
Cerebrane is an injection of porcine brain peptide and is effective for ▲ senile dementia (Alzheimer's and vascular dementia) ▲ brain dysfunction after stroke ▲ traumatic brain injury (concussion, brain injury).
While most of the same-component drugs currently on the market in Korea are in a single 10ml dose, Daewoong Bio differentiated itself from other companies by releasing CereBrain in two doses, 10ml and 20ml. Pig brain peptides are administered up to 50ml depending on symptoms, so Cerebrain, which has a two-dose lineup, is not only highly convenient for prescription, but the 20ml product is about 30% cheaper than the two 10ml products, which reduces the burden of treatment costs for patients.
Daewoong Bio will soon release a 30ml formulation. A wide range of treatments is possible with only 1 vial, which will not only increase convenience but also enable supply at economic drug prices. In addition, Cerebrain is made of a 'vial' container, so it is more safe to administer than ampoule container products.
Yoo Young-ki, head of Daewoong Bio's marketing division, said "Serebrain is being reborn as a market-leading product based on its wide range of indications, formulation benefits, and excellent safety and effectiveness."We will make all-out efforts to improve consumer quality of life through patient-centered development strategies such as launching new formulations."
This article was translated by Naver AI translator.
